




RealRate

# MEDICINAL PRODUCTS 2022

Oncocyte Corp  
Rank 35 of 51





# MEDICINAL PRODUCTS 2022

Oncocyte Corp  
Rank 35 of 51



The relative strengths and weaknesses of Oncocyte Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncocyte Corp compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Oncocyte Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is -6.8%, being 6.7% points above the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	39,143
Assets, Non-Current	264
General and Administrative Expense	37,688
Goodwill	109,929
Liabilities, Current	14,120
Liabilities, Non-Current	0
Other Assets	10,227
Other Compr. Net Income	37
Other Expenses	21,359
Other Liabilities	80,226
Other Net Income	854
Other Revenues	7,727
Property, Plant and Equipment, Net	0
Research and Development	13,631

Output Variable	Value in 1000 USD
Liabilities	94,346
Assets	159,563
Expenses	72,678
Revenues	7,727
Stockholders Equity	65,217
Net Income	-64,097
Comprehensive Net Income	-64,078
Economic Capital Ratio	-6.8%